首页> 美国卫生研究院文献>Experimental and Therapeutic Medicine >Declines in serum CYFRA21-1 and carcinoembryonic antigen as predictors of chemotherapy response and survival in patients with advanced non-small cell lung cancer
【2h】

Declines in serum CYFRA21-1 and carcinoembryonic antigen as predictors of chemotherapy response and survival in patients with advanced non-small cell lung cancer

机译:血清CYFRA21-1和癌胚抗原的下降是晚期非小细胞肺癌患者化疗反应和生存率的预测指标

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The aim of this study was to investigate the clinical value of serum cytokeratin 19 fragment (CYFRA21-1) and carcinoembryonic antigen (CEA) in the prediction of chemotherapy response and prognosis in patients with advanced non-small cell lung cancer (NSCLC). Serum CYFRA21-1 and CEA levels of 98 patients with advanced NSCLC were measured using immunoradiometric kits prior to and after 2 cycles of chemotherapy. After 2 cycles of chemotherapy, 45 patients achieved a radiological objective response (OR), 30 patients achieved stable disease (SD) and 23 patients had progressive disease (PD). Serum CYFRA21-1 and CEA were significantly decreased compared to baseline levels (P<0.001). By ROC curve analysis, a ≥60% reduction in CYFRA21-1 and a ≥25% reduction in CEA were the optimal cut-off levels with best sensitivity and specificity for the diagnosis of radiologic OR. The median survival of all patients was 10.2 months (range 2.6–26.3). Univariate survival analysis showed that the Eastern Cooperative Oncology Group (ECOG) performance status (PS) score, radiologic OR, a ≥60% reduction in CYFRA21-1 and a ≥25% reduction in CEA were significant prognostic factors for better overall survival. The median overall survival time in patients with a ≥60% reduction in CYFRA21-1 was significantly longer than in those with a <60% reduction (P<0.001). Similarly, the median overall survival time in patients with a ≥25% reduction in CEA was also significantly longer than in those with a <25% reduction (P<0.001). Multivariate analysis showed that ECOG PS score, a ≥60% reduction in CYFRA21-1 and a ≥25% reduction in CEA were independent prognostic factors of survival, while radiologic OR was not. In conclusion, a ≥60% reduction in CYFRA21-1 and a ≥25% reduction in CEA may be reliable surrogate markers for the prediction of chemothrapy response and prognosis, especially for the diagnosis of radiologic OR.
机译:这项研究的目的是研究血清细胞角蛋白19片段(CYFRA21-1)和癌胚抗原(CEA)在预测晚期非小细胞肺癌(NSCLC)患者化疗反应和预后中的临床价值。在2个疗程的化疗前后,使用免疫放射试剂盒测量了98例晚期NSCLC患者的血清CYFRA21-1和CEA水平。经过2个周期的化疗,有45例患者达到了放射学客观反应(OR),有30例患者达到了稳定疾病(SD),有23例患者患有进行性疾病(PD)。与基线水平相比,血清CYFRA21-1和CEA显着降低(P <0.001)。通过ROC曲线分析,CYFRA21-1降低≥60%和CEA降低≥25%是最佳阈值水平,对放射性OR的诊断具有最佳敏感性和特异性。所有患者的中位生存期为10.2个月(范围2.6–26.3)。单因素生存分析表明,东部合作肿瘤小组(ECOG)的表现状态(PS)评分,放射学OR,CYFRA21-1降低≥60%和CEA降低≥25%是改善总体生存率的重要预后因素。 CYFRA21-1降低≥60%的患者的中位总体生存时间显着长于<60%降低的患者(P <0.001)。同样,CEA降低≥25%的患者的中位总体生存时间也显着长于CEA降低≥25%的患者(P <0.001)。多因素分析显示,ECOG PS评分,CYFRA21-1降低≥60%和CEA降低≥25%是生存的独立预后因素,而放射学OR则不是。总之,CYFRA21-1减少≥60%和CEA减少≥25%可能是预测化学疗法反应和预后的可靠替代指标,尤其是对于放射性OR的诊断。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号